Managing Obesity as a Chronic Disease: A Pathophysiologic Approach to Cardiometabolic Risk Reduction CME

Scott M. Grundy, MD, PhD, Chair; Christopher P. Cannon, MD; Samuel Klein, MD; F. Xavier Pi-Sunyer, MD, MPH Author Information and Disclosures

Release Date: January 7, 2008Valid for credit through January 7, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s) for physicians

This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Managing Obesity as a Chronic Disease: A Pathophysiologic Approach to Cardiometabolic Risk Reduction" symposium held at the Rosen Plaza Hotel in Orlando, Florida, on November 4, 2007.

To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 SciMed


Merck

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Recognize the need for long-term management and maintenance of weight reduction in obesity to reduce cardiovascular risk.
  2. Describe the neurobiological role of the endocannabinoid system in obesity and evaluate its potential as a target for novel therapies.
  3. Design and implement long-term weight management strategies that integrate pharmacotherapy and behavior modification.
Author Disclosures

Scott M. Grundy, MD, PhD
Disclosure: Grant/Research Support: Abbott Laboratories, Kos Pharmaceuticals, Merck & Co., Inc.; Consultant: Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Fournier, GlaxoSmithKline, Kos Pharmaceuticals, Merck & Co., Inc., Merck/Schering-Plough, Pfizer Inc, Sankyo, sanofi-aventis


Christopher P. Cannon, MD
Disclosure: Grant/Research Support: Accumetrics, AstraZeneca, GlaxoSmithKline, Merck & Co., Inc., Merck/Schering-Plough, Schering-Plough Pharmaceuticals


Samuel Klein, MD
Disclosure: Consultant: Merck & Co., Inc.


F. Xavier Pi-Sunyer, MD, MPH
Disclosure: Grant/Research Support: sanofi-aventis; Consultant: sanofi-aventis


 
SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SciMed designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.